Dimerix (ASX:DXB) has confirmed that the first clinical trial site in Japan is now open for recruitment, triggering the first development milestone payment of ¥400 million (~AU$4.3 million) from FUSO Pharmaceutical Industries, the exclusive licensee of DMX-200 for FSGS in Japan. …
Dimerix says first ACTION3 trial site activated in Japan and first milestone payment triggered
May 30, 2025 Australian Biotech
Latest Video
New Stories
-
Genomic testing to reach more patients with hard to treat cancers
September 17, 2026 - - Latest News -
Eight women named finalists for 2026 Marie Krogh Young Women in Science Prize
September 17, 2026 - - Latest News -
'Your success makes you a target and take it as a compliment'
September 16, 2026 - - Latest News -
New Zealand ranks last among wealthy nations on modern medicines access, new report finds
September 16, 2026 - - Latest News -
Young Australians badly misjudge when fertility starts to decline, new survey finds
September 16, 2026 - - Latest News -
New research points to a 'Doctor gap' holding back clinical trial participation in Australia
September 16, 2026 - - Latest News -
From constitutional promise to creaking system - the PBS at 80
September 16, 2026 - - Latest News